Showing papers by "Roger Stupp published in 1995"
Journal Article•
TL;DR: The study goals are to establish the maximum tolerated dose and dose-limiting toxicity of paclitaxel when added to this combination as a 5-day continuous infusion on a biweekly schedule and to demonstrate activity in patients with poor-prognosis head and neck cancer.
23 citations
Journal Article•
TL;DR: This ongoing study is testing the feasibility of adding continuous-infusion paclitaxel (Taxol) to this combination of 5-fluorouracil, hydroxyurea, and concomitant chemoradiotherapy to treat advanced head and neck cancer.
16 citations
01 Jan 1995
TL;DR: Several randomized trials suggest improved locoregional control with concomitant chemoradiotherapy with 5-fluorouracil-based chemotherapy regimen, which seems to improve treatment outcome.
Abstract: 5-fluorouracil is a widely used chemotherapeutic agent. Its role and activity in the treatment of squamous cell carcinoma of the head and neck are reviewed. In head and neck cancer, 5-fluorouracil is mostly used in combination with cisplatin. Despite a high activity of this regimen, as documented in response rates of up to 90%, its use as an adjuvant to surgery and radiation does not impact consistently on survival rates. In contrast, 5-FU-based chemotherapy with concomitant radiotherapy seems to improve treatment outcome. Several randomized trials suggest improved locoregional control with concomitant chemoradiotherapy with a 5-fluorouracil-based chemotherapy regimen. The activity and the metabolism of 5-FU can be further modulated by cisplatin, hydroxyurea, and leucovorin.
7 citations